Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

John Chapman Articles

PlayFOURIER update: new impetus for guideline groups to reconsider LDL targets

FOURIER update: new impetus for guideline groups to reconsider LDL targets

  ESC Congress 2017: Not lower is better but lowest is best, according to findings from a new analysis from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial with the PCSK9 inhibitor evolocumab (1). According to lead author…

read more »
PlayImplications of very low LDL cholesterol levels

Implications of very low LDL cholesterol levels

One of the key concerns of clinicians in the aftermath of FOURIER is the safety of very low LDL cholesterol levels. This is underlined by the fact that 42% of patients on evolocumab in FOURIER attained LDL cholesterol levels ≤25 mg/dl (0.65 mmol/L).(1) As previously…

read more »
New EAS Consensus Panel Statement: LDL causes ASCVD

New EAS Consensus Panel Statement: LDL causes ASCVD

85rd Annual Congress of the European Atherosclerosis Society (EAS), April 23-26th, Prague, Czech Republic Yesterday the EAS Consensus Panel published a new Consensus Statement confirming that LDL causes ASCVD. While there has been extensive evidence implicating LDL as a major modifiable cardiovascular risk factor, others…

read more »
PlayThe Word from ACC 2017 – Implications for Practice

The Word from ACC 2017 – Implications for Practice

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board discuss implications from FOURIER for clinical practice.

read more »
PlayThe Word from ACC 2017  – Key Results

The Word from ACC 2017 – Key Results

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board dissect the key results and messages from FOURIER.

read more »
PlayFOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER was a landmark trial for PCSK9 inhibition, showing significant reduction in cardiovascular events with evolocumab in very high risk patients on maximally tolerated lipid lowering therapy. The results from FOURIER, together with those from SPIRE-2 in patients at higher baseline LDL cholesterol levels, clearly…

read more »
A landmark day for PCSK9 inhibition

A landmark day for PCSK9 inhibition

What a landmark day for lipid lowering. All eyes were focused on FOURIER at the first of the late-breaking clinical trial sessions at ACC.2017. And the results didn’t disappoint. In patients with stable cardiovascular disease on maximally tolerated statin therapy, evolocumab treatment lowered LDL cholesterol…

read more »
PlayLooking back at 2016: What made the news?

Looking back at 2016: What made the news?

PCSK9 Forum Editor Professor John Chapman reviews the ups and downs of LDL lowering news in 2016. The Highlights GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound) (1) would have to feature very much in the forefront of…

read more »
GLAGOV in context: A view from the PCSK9 Forum Editors

GLAGOV in context: A view from the PCSK9 Forum Editors

The results of GLAGOV, reported at AHA Scientific Sessions and now published in JAMA (1) are of keen interest to the clinical community, with the major outcomes study FOURIER with evolocumab expected early in 2017. PCSK9 Forum Editors Professor Henry Ginsberg and Professor John Chapman…

read more »
Bococizumab exits the PCSK9 stage: A response from PCSK9 Forum Editors

Bococizumab exits the PCSK9 stage: A response from PCSK9 Forum Editors

Pfizer announced on Tuesday, 1st November that it was discontinuing development of bococizumab, its PCSK9 inhibitor. According to the press release, the Company stated that: ‘The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering…

read more »
PCSK9 inhibition at the limits

PCSK9 inhibition at the limits

With the PCSK9 inhibitors, are we now at the limit for LDL-C lowering? And if so, which patients are the priorities for this novel therapy in clinical practice? PCSK9 Forum Co-Editor Professor John Chapman discusses these important questions in this video. Pause 100/100 Production and…

read more »
The year in cardiology 2015: prevention

The year in cardiology 2015: prevention

PCSK9 Forum Editors, Profs John Chapman, Ulf Landmesser and co-authors discuss the highlights of 2015 in The European Heart Journal.  

read more »
From the Editors: PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

From the Editors: PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

PCSK9 Forum Editors overview recent developments in PCSK9 science and therapeutics, culminating in regulatory approval of the first two PCSK9 monoclonal antibodies earlier this year. While access to this novel LDL lowering treatment will undoubtedly be influenced by local cost constraints, the editors highlight severe…

read more »
PlayNew era in cholesterol-lowering? PCSK9 inhibitors soon available?

New era in cholesterol-lowering? PCSK9 inhibitors soon available?

European authority (CHMP) has recommended regulatory approval of the first PCSK9 inhibitor, opening the way to a new era of lowering LDL-cholesterol treatment for people with a high risk of heart attacks and strokes. The importance of this development and possible implications for patients with…

read more »
Is there a need for a unified definition for FH?

Is there a need for a unified definition for FH?

2014 FH Global Summit: 13-14 October, New York, USA: FH is clearly underdiagnosed and undertreated in the majority of countries.1 Given this status quo, would the development of a unified global definition of FH offer advantages for detection, management and health policy? In the FH…

read more »